#1 Clinical Trials Search in Europe

Study on Long-term Safety and Efficacy of Mexiletine for Children with Myotonic Disorders

1 1 1 1

What is this study about?

This clinical trial is focused on studying the long-term safety and effectiveness of a medication called Mexiletine in children with certain muscle disorders known as myotonic disorders. These disorders include nondystrophic myotonias and myotonic dystrophies, which can cause muscle stiffness and difficulty relaxing muscles after use. The study involves children who have already participated in previous studies and tolerated the medication well.

The treatment being tested includes different doses of Mexiletine in the form of hard capsules, specifically Mexiletine 62 mg, Mexiletine 83 mg, and Namuscla 167 mg. The purpose of the study is to gather more information about how safe and effective Mexiletine is for treating symptoms of muscle stiffness in children over a longer period. Participants will take the medication by mouth and will be monitored regularly to check for any side effects and to see how well the medication is working in reducing muscle stiffness.

Throughout the study, the children will have their muscle stiffness assessed using simple scales and tests. These assessments will help determine any changes in their condition over time. The study will also look at the overall quality of life of the participants and any changes in their health. The goal is to ensure that Mexiletine is a safe and effective treatment option for children with these muscle disorders.

1 joining the study

Participation begins after completing the initial study MEX-NM-301 and tolerating the medication mexiletine.

Assent from the patient and consent from a parent or guardian are required.

2 medication administration

The medication mexiletine is administered in the form of hard capsules.

Dosages include Mexiletine 62 mg, Mexiletine 83 mg, and Namuscla 167 mg.

The medication is taken orally.

3 monitoring and assessments

Adverse events are monitored throughout the study.

Every 3 months, changes in muscle stiffness are assessed using a Visual Analogue Scale (VAS) or Faces score.

Every 6 months, handgrip myotonia is measured using a grip dynamometer.

4 additional evaluations

Every 3 months, changes in vital signs and clinical laboratory values are recorded.

Every 6 months, clinical myotonia assessments are conducted, including tests for eyelid myotonia and flexor myotonia.

Quality of life is evaluated using the Paediatric Quality of Life (PedsQL) score.

5 study duration

The study is estimated to conclude by June 13, 2026.

Who Can Join the Study?

  • The patient must have completed a previous study called MEX-NM-301 and tolerated the medication Mexiletine during that study.
  • The patient must be able and willing to agree to participate in the study, and a parent or legal guardian must be willing to sign a written consent form before the study begins.
  • The patient must continue to meet the requirements of the previous study, MEX-NM-301.
  • The study is open to both male and female patients.

Who Cannot Join the Study?

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Hopital Necker Enfants Malades Paris France

Other Sites

Site Name City Country Status
Assistance Publique Hopitaux De Paris Paris France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Recruiting
03.11.2021

Trial locations

Investigated drugs:

Mexiletine is a medication being studied for its long-term safety and effectiveness in treating myotonia, a condition that affects muscle relaxation, in children. This study is an extension of previous research, aiming to gather more information on how well mexiletine works and how safe it is for young patients who have already participated in earlier trials.

Myotonic Disorders – Myotonic disorders are a group of conditions characterized by prolonged muscle contractions, known as myotonia, which can cause stiffness and difficulty in relaxing muscles after use. These disorders include nondystrophic myotonias and myotonic dystrophies, such as type 1 and type 2. Nondystrophic myotonias are typically caused by genetic mutations affecting ion channels in muscle cells, leading to abnormal muscle excitability. Myotonic dystrophies, on the other hand, are progressive conditions that not only affect muscles but can also impact other systems in the body, such as the heart and eyes. Symptoms often begin in childhood or early adulthood and can vary widely in severity. Over time, individuals may experience increasing muscle weakness and stiffness, impacting daily activities.

Trial ID:
2024-513484-89-00
Protocol code:
MEX-NM-303
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Evaluation of mRNA-4359 Monotherapy and Combined Pembrolizumab Therapy in Advanced Solid Tumors: A Phase 1/2 Clinical Trial

    Recruiting

    1 1 1
    Investigated drugs:
    Germany Italy Poland Spain

  • Phase 1/2 Evaluation of Zilovertamab Vedotin in PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark Italy The Netherlands Spain